News | May 20, 2011

New Data Confirms Safety of BioMatrix at One Year

May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has confirmed that BioMatrix, Biosensors’ Biolimus A9-eluting stent system with abluminal bioresorbable polymer, is safe over a 12-month period in a “real-world” patient population.

The e-BioMatrix PMS Registry, initiated in March 2008, is a prospective, multi-center, observational registry to assess the outcomes of over 1,000 “real-world” patients across nine European study sites over a five-year period. Enrollment was completed in September 2009. All patients are being comprehensively monitored, including for baseline information, index hospitalization and the patient file until last reported cardiac-related event. The primary endpoint of the registry was MACE (a composite of cardiac death, MI and clinically-driven TVR) at 12 months. Of the 1102 patients studied over this period, 74 (6.7%) experienced a clinical adverse event that could be included in the primary endpoint according to the independent Critical Events Committee. The registry will also examine a range of secondary endpoints, including primary and stent thrombosis over several periods; MACE at intervals up to five years; and death and MI rates for up to five years.

A broad range of inclusion criteria have ensured that e-BioMatrix is a “real-world” registry: patients have had to be at least 18 years old; need treatment with a DES; and have one or more coronary artery stenoses in a native coronary artery or a saphenous bypass graft from 2.25 to 4.0 mm in diameter that can be covered with one or multiple stents. There have been no limitations on the number of treated lesions, vessels, or lesion length.

“These registry findings provide further reassurance on the safety of a biolimus-eluting stent with biodegradable polymer in a wide range of patient types requiring PCI that we routinely see in our daily practice,” said principal investigator Dr. Philip Urban, La Tour Hospital, Geneva, Switzerland. “The results are especially reputable due to the high levels of follow-up that have been achieved, with 97.6 percent at one year.”

A similar registry to e-BioMatrix PMS, the e-BioMatrix Post-Marketing Registry (PMR), was initiated at the same time, involving up to 4,800 patients. The protocols of the two studies are identical, with e-BioMatrix PMR monitoring for reported cardiac-related events only. Enrollment for this second registry is due to be completed by October 2011.

The PMS registry solely involved patients given the original BioMatrix, whereas the PMR involved patients given both BioMatrix and BioMatrix Flex. Introduced in May 2010, BioMatrix Flex incorporates an improved mechanical platform for enhanced deliverability, whilst retaining the Biosensors-developed abluminally-coated biodegradable polymer and Biolimus A9, an anti-restenotic drug developed by Biosensors exclusively for use with drug-eluting stents, as used in the original BioMatrix stent system.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init